Familial amyloidosis with polyneuropathy type 1 caused by transthyretin mutation Val50Met (Val30Met): 4 cases in a non-endemic area by Andrés, N. et al.
Neurología. 2018;33(9):583—589
NEUROLOGÍA
www.elsevier.es/neurologia
ORIGINAL ARTICLE
Familial  amyloidosis  with  polyneuropathy  type  1
caused by  transthyretin  mutation  Val50Met  (Val30Met):
4 cases  in a non-endemic  area,
N. Andrésa,∗, J.J. Pozaa, J.F. Martí Massóa,b
a Servicio  de  Neurología,  Hospital  Universitario  Donostia,  San  Sebastián,  Spain
b Área  de  Neurociencias,  Universidad  del  País  Vasco,  San  Sebastián,  Spain
Received  12  May  2016;  accepted  20  July  2016
Available  online  23  August  2018
KEYWORDS
Transthyretin;
Hereditary  amyloid
polyneuropathy;
Val50Met  (Val30Met);
Amyloid
Abstract
Introduction:  Transthyretin-related  familial  amyloid  polyneuropathy  (TTR-FAP)  typically  arises
as an  autonomic  neuropathy  primarily  affecting  small  ﬁbres  and  it  occurs  in  adult  patients  in
their second  or  third  decades  of  life.  It  progresses  rapidly  and  can  lead  to  death  in  approximately
10 years.  Other  phenotypes  have  been  described  in  non-endemic  areas.
Objectives  and  methods:  We  described  4  cases  from  the  Spanish  province  of  Guipuzcoa,  a
non-endemic  area,  to  highlight  the  clinical  variability  of  this  disease.
Patients  and  results:  Three  patients  presented  a  late-onset  form  manifesting  after  the  age  of
50, featuring  a  predominantly  motor  polyneuropathy  initially  causing  distal  impairment  of  the
lower limbs  followed  by  the  upper  limbs.  One  patient  suffered  severe  neuropathic  pain.  None
showed  signs  of  autonomic  involvement.  The  fourth  patient,  of  Portuguese  descent,  presented
a typical  form  with  onset  in  her  thirties,  neuropathic  pain  and  dysautonomia.  All  patients  carry
the Val50Met  mutation  in  the  TTR  gene.
Conclusion:  FAP  is  a  pleomorphic  disease  even  in  patients  carrying  the  same  mutation.  In
non-endemic  areas,  its  main  form  of  presentation  may  resemble  a  predominantly  motor
polyneuropathy  developing  in  the  sixth  decade  of  life  with  no  signs  of  dysautonomia.  Given Please cite this article as: Andrés N, Poza JJ, Massó JFM. Polineuropatía amiloidótica familiar I por mutación Val50Met (Val30Met) en
el gen de la transtiretina. Neurología. 2018;33:583—589.
 This study was awarded the prize for Best Oral Presentation at the 37th Meeting of the Neurology Society of the Basque Country,
held at Hotel Monte Igueldo in San Sebastián on 26 and 27 February 2016.
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this  non-speciﬁc  presentation  and  the  widely  available  technical  means  of  studying  the  TTR
gene, we  believe  that  the  protocol  for  the  aetiological  diagnosis  of  any  polyneuropathy  should
include genetic  sequencing  of  TTR.
© 2016  Sociedad  Espan˜ola  de  Neurolog´ıa.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an  open
access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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Polineuropatía  amiloidótica  familiar  I  por  mutación  Val50Met  (Val30Met)  en  el  gen  de
la  transtiretina
Resumen
Introducción:  La  polineuropatía  amiloidótica  familiar  por  transtiretina  (PAF  por  TTR)  cursa
inicialmente  con  una  afectación  preferente  de  ﬁbra  ﬁna  e  importante  afectación  autonómica,
con un  inicio  en  la  segunda-tercera  década  de  la  vida  y  una  evolución  rápidamente  progresiva
que puede  llevar  a  la  muerte  del  paciente  en  unos  10  an˜os.  Sin  embargo,  en  zonas  no  endémicas,
se han  descrito  otros  fenotipos.
Objetivos  y  métodos:  Describimos  4  casos  procedentes  de  una  zona  no  endémica,  la  provincia
de Guipúzcoa,  con  el  objetivo  de  mostrar  la  variabilidad  clínica  de  esta  enfermedad.
Pacientes  y  resultados:  Tres  pacientes  presentaron  una  forma  de  inicio  tardío,  por  encima  de
los 50  an˜os,  que  cursó  como  una  polineuropatía  de  predominio  motor  con  afectación  distal  inicial
en miembros  inferiores  y  posteriormente  en  los  superiores.  Uno  sufrió  dolor  neuropático  intenso.
Ninguno  tuvo  signos  de  afectación  autonómica.  La  cuarta  paciente,  de  origen  portugués,  pre-
sentó una  forma  típica  de  inicio  en  la  treintena,  con  dolor  neuropático  y  disautonomía.  Los  4
pacientes  presentan  la  mutación  Val50Met  en  el  gen  TTR.
Conclusión:  La  PAF  es  una  enfermedad  pleomórﬁca  incluso  en  pacientes  con  la  misma
mutación.  En  zonas  no  endémicas,  su  presentación  predominante  puede  ser  como  una
polineuropatía  de  inicio  por  encima  de  la  sexta  década,  de  predominio  motor  y  sin  signos
disautonómicos.  Dado  lo  inespecíﬁco  de  esta  forma  de  presentación  y  la  facilidad  técnica  con
la que  se  puede  estudiar  actualmente  el  gen  TTR,  creemos  que  en  el  protocolo  de  diagnóstico
etiológico  de  cualquier  polineuropatía  se  debe  incluir  la  secuenciación  de  este  gen.
© 2016  Sociedad  Espan˜ola  de  Neurolog´ıa.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este  es  un
art´ıculo Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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ransthyretin  familial  amyloid  polyneuropathy  (TTR-FAP)  is
 genetic,  multisystem  disease  caused  by  mutation  of  the
TR  gene.1—7 Corinho  Andrade  ﬁrst  described  the  condition
n  1952  in  northern  Portugal,2,3,8 where  it  is  colloquially
eferred  to  as  mal  dos  pezinhos.5
The  disease  is  most  frequent  in  3  endemic  foci,  in  Portu-
al,  Sweden,  and  Japan.2,4,5,8,9 The  most  signiﬁcant  foci  in
pain  are  located  on  the  island  of  Mallorca7—9 and  in  Valverde
el  Camino  (province  of  Huelva).7 The  Basque  Country  is  a
on-endemic  area.  Prevalence  of  TTR-FAP  is  estimated  at
/10  000  population  globally1 and  1/100  000  population  in
urope.7,8
TTR  is  a  short  gene,  containing  only  4  exons,  located
n  the  short  arm  of  chromosome  18  (18q12.1).5 Over  100
utations  have  been  described  in  association  with  the
ene.  The  most  frequent  mutation  is  a  valine-to-methionine
ubstitution  at  position  30  (Val30Met  or  V30M,  now  denomi-
ated  Val50Met  due  to  an  update  to  the  reference  sequence
c
a
pntailing  a  change  in  the  order  of  amino  acids)  of  the  127
mino  acid  sequence.1—8
Transmission  mainly  follows  an  autosomal  dominant  pat-
ern  of  inheritance,7,8 although  sporadic  and  de  novo
ases  have  also  been  reported.5 Penetrance  is  highly  vari-
ble,  and  differs  according  to  the  mutation  and  endemic
ocus.5—8 Early  symptom  onset  and  increased  penetrance
ave  been  associated  with  maternal  transmission  of  the
utation.5,8
TTR  is  an  amyloid  precursor  protein  which  transports  thy-
oxine  and  vitamin  A.1,5—8 It  is  mainly  synthesised  in  the
iver  (95%),  but  is  also  expressed  in  the  retina  and  choroid
lexuses.  The  protein  circulates  as  a  tetramer  in  the  blood
nd  the  cerebrospinal  ﬂuid.  TTR  mutations  destabilise  the
etramer,  giving  rise  to  abnormally  folded  monomers  which
re  distributed  patchily  in  various  tissues,  especially  in  the
eripheral  nervous  system  and  the  heart.1,5—7
The  variability  in  the  age  of  symptom  onset  and  the
linical  presentation  of  TTR-FAP,  especially  in  non-endemic
reas,  makes  diagnosing  the  condition  a  complex,  lengthy
rocess.
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PFamilial  amyloidosis  with  polyneuropathy  type  1  caused  by  T
Patients, methods, and results
We  describe  the  clinical  variability  of  TTR-FAP  as  observed
in  4  identiﬁed  patients  consulting  at  the  Hospital  Univer-
sitario  Donostia  neurology  department  between  2005  and
2016.
Patient  1
Patient  1  was  a  58-year-old  man  from  Navarre  who  attended
the  neurology  department  in  December  2013  due  to  a  1-
year  history  of  fatigue  and  a  ‘‘strange’’  sensation  in  the
feet.  In  recent  months,  he  had  experienced  a  similar  sen-
sation  in  the  hands,  hindering  certain  ﬁne  movements,
such  as  opening  a  clothes  peg.  He  displayed  no  signs  of
dysautonomia.
The  patient  had  no  relevant  history  except  left-sided
amblyopia  since  infancy  and  surgery  for  retinal  detachment
and  cataracts.  The  neurological  examination  identiﬁed  no
abnormalities,  except  mild  weakness  in  dorsiﬂexion  of  the
ankles  and  a  mild  sensory  alteration  in  a  ‘‘stocking’’  pattern.
The  complete  blood  count  and  urine  sediment  test
(including  microalbumin  determination)  yielded  normal
results.  An  electromyography  study  of  the  short  thumb
abductor  and  the  left  tibialis  anterior  muscle  showed  no
alterations.  Electroneurography  ﬁndings  were  compatible
with  axonal  sensorimotor  polyneuropathy  with  predomi-
nance  of  sensory  alterations.  A  sural  nerve  biopsy  revealed
a  severe  axonal  neuropathy  with  no  amyloid  deposition  and
no  sign  of  vasculitis.
Both  motor  and  sensory  symptoms  worsened  progres-
sively.  In  August  2015,  the  patient’s  uncle  was  diagnosed
with  an  amyloid  neuropathy  after  a  sural  nerve  biopsy.
This  led  us  to  order  sequencing  of  the  TTR  gene,  which
revealed  the  c.148G>A  (p.Val50Met)  mutation  in  heterozy-
gosis.  An  echocardiogram  revealed  amyloid  deposition
on  the  interventricular  septum  and  mild  diastolic  dys-
function.  An  ophthalmological  examination  detected  no
amyloid  deposition.  Treatment  was  started  with  triﬂusal  and
bisoprolol.
We  performed  a  genetic  study  of  the  family  to  iden-
tify  potential  carriers  of  the  mutation.  The  patient’s
aunt  and  brother,  aged  87  and  68,  respectively,  carried
the  Val50Met  mutation,  but  presented  no  symptoms  or
alterations.
Patient  2
Patient  2  was  a  77-year-old  man  from  Gipuzkoa  who
attended  the  department  complaining  of  a  2-year  history
of  fatigue,  pain,  and  a  tingling  sensation  in  the  feet,
interfering  with  his  ability  to  walk;  he  also  reported  a
tingling  sensation  in  the  ﬁngers.  He  displayed  no  signs  of
dysautonomia.
He  had  a  history  of  arterial  hypertension  (treated  with
indapamide)  and  constipation  (treated  with  isphagula  husk).
His  parents  had  died  at  the  ages  of  96  and  92,  with  no
neurological  diseases.  He  had  4  older  siblings  (aged  87,  84,
82,  and  81),  with  no  relevant  family  history  of  neurological
problems.
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The  neurological  examination  revealed  paralysis  of  the
istal  muscles  of  the  legs;  amyotrophy  of  the  thenar  emi-
ence  and  the  interosseous  muscles  of  the  hands;  reduced
ouch,  pain,  and  vibration  sensation  in  a  ‘‘stocking’’  dis-
ribution  and  in  the  ﬁngers;  universal  areﬂexia;  and  mildly
taxic  gait  with  bilateral  steppage.
The  complete  blood  count  and  urine  sediment  test
ielded  normal  results.  Electroneurography  ﬁndings  were
ompatible  with  severe  axonal  sensorimotor  polyneuro-
athy  with  predominance  of  sensory  alterations.  A  sural
erve  biopsy  detected  amyloid  deposits  destroying  the  nerve
bres;  the  deposits  were  positive  for  Congo  red  staining
Fig.  1).
TTR  gene  sequencing  was  ordered,  revealing  the
al50Met  mutation  in  heterozygosis.
atient  3
he  patient  was  a  32-year-old  woman  from  Portugal;  her
eceased  father  had  been  diagnosed  with  TTR-FAP  due  to
he  Val50Met  mutation.  Her  father’s  4  siblings  (2  men  and  2
omen)  and  both  paternal  grandparents  displayed  the  same
isease.  She  attended  our  department  in  2006  for  a  genetic
tudy.  The  physical  and  neurological  examinations  and  labo-
atory  and  neurophysiological  studies  performed  at  the  time
ielded  normal  results.  The  genetic  study  detected  the  same
utation  in  heterozygosis.  The  patient  received  genetic
ounselling  and  preimplantation  genetic  diagnosis,  as  she
ntended  to  have  children.  In  July  2015,  she  attended  a
onsultation  at  our  department  due  to  intense  low  back  pain
adiating  to  both  lower  limbs,  together  with  burning  and  tin-
ling  sensations,  allodynia,  and  oedema  in  the  feet.  A month
arlier,  she  experienced  alternating  diarrhoea  and  constipa-
ion  and  marked  abdominal  distension.  The  patient  reported
nstability  and  dizziness  upon  walking.  She  had  no  other
ssociated  symptoms,  and  presented  no  signs  or  symptoms
f  orthostatic  hypotension.  She  was  receiving  treatment
ith  venlafaxine,  alprazolam,  and  mirtazapine  due  to  reac-
ive  anxiety  in  response  to  the  presymptomatic  diagnosis
f  the  disease.  The  neurological  examination  found  normal
ouch,  pain,  and  vibration  sensation;  deep  tendon  reﬂexes;
nd  muscular  balance.  The  echocardiogram  revealed  left
trial  enlargement,  with  no  additional  alterations.  A  Holter
CG  study  detected  infrequent  ventricular  extrasystoles.
 bone  scan  revealed  no  abnormalities.  Suspecting  initial
TR-FAP  symptom  manifestation,  we  started  treatment  with
afamidis,  plus  duloxetine  for  pain  control.  As  duloxetine
as  unsuccessful,  we  later  prescribed  eslicarbazepine;  this
as  also  ineffective,  and  substituted  with  tapentadol  and
iazepam.  In  February  2016,  the  patient  displayed  thermal
ypoaesthesia  in  the  feet  and  distal  third  of  the  legs;  no
ther  abnormalities  were  found.  Given  the  persistence  of
ntense,  refractory  neuropathic  pain,  a liver  transplant  was
rdered  in  February  2016;  the  operation  was  performed  2
eeks  ago.
atient  4he  patient  was  a 64-year-old  former  smoker  from  Gipuzkoa,
ith  no  relevant  personal  history.  He  attended  the  neurol-
gy  department  in  March  2005  due  to  cramps  and  allodynia
586  N.  Andrés  et  al.
Figure  1  Sural  nerve  biopsy.  Haematoxylin  and  eosin  (A  and  B)  and  Congo  red  (C  and  D)  staining.  The  endoneurium  shows
amorphous, eosinophilic  hyaline  deposits  that  are  positive  for  Congo  red.
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2,3,5n  the  soles  of  the  feet  and  difﬁculty  climbing  stairs,
hich  had  started  3  years  earlier.  His  younger  brother  and
eceased  sister  had  both  experienced  similar  symptoms
nd  been  diagnosed  with  TTR-FAP.  Both  siblings  underwent
iver  transplantation.  The  neurological  examination  was  nor-
al  except  for  reduced  touch  and  vibration  sensation  in  a
‘stocking’’  distribution,  absent  Achilles  reﬂex,  and  patellar
endon  hyporeﬂexia.  A  complete  blood  count  detected  no
bnormalities.  A  neurophysiological  study  revealed  axonal
ensorimotor  polyneuropathy.  A  genetic  study  identiﬁed  the
al50Met  mutation  in  heterozygosis.  Holter  ECG  monitoring
howed  frequent  supraventricular  extrasystoles  with  mul-
iple  salvos  of  supraventricular  tachycardia.  No  alterations
ere  detected  in  the  tilt-table  test.  We  attempted  to  con-
rol  neuropathic  pain  with  pregabalin  and  amitriptyline.
ymptoms  continued  to  progress,  with  the  patient  develop-
ng  motor  deﬁcits  in  the  lower  limbs,  affecting  gait.  Despite liver  transplant  performed  in  2007,  neuropathic  pain  con-
inued  to  increase  in  intensity;  duloxetine  was  added  to
he  patient’s  treatment  schedule.  The  patient  developed
onstipation  and  oedema  of  the  feet.  The  neurological
s
i
t
pymptoms  remained  largely  stable,  with  distal  weakness  in
he  hands  and  feet  and  neuropathic  pain;  the  patient  was
ble  to  walk  with  a  cane.  Cardiac  involvement  progressed,
nd  the  patient  died  of  heart  failure  9  years  after  diagno-
is.
iscussion
he  most  common  manifestation  of  TTR-FAP,  described
y  Andrade  in  the  Portuguese  variant  caused  by  the
al50Met  mutation,  is  a  sensorimotor  polyneuropathy  pre-
enting  with  autonomic  dysfunction,  with  onset  occurring
etween  the  ages  of  30  and  40  years.2—8,10 The  condition  ini-
ially  affects  the  small  myelinated  (A)  and  non-myelinated
bres  responsible  for  transmitting  pain  and  temperature
ignals. The  greater  the  length  of  an  axon,  the  greater
ts  exposure  to  amyloid  deposition  and  the  resulting  func-
ional  alteration.2,5 This  explains  the  way  the  disease
rogresses,  initially  involving  distal  segments  and  eventually
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affecting  more  proximal  areas.2,3,5,7 The  natural  history  of
the  disease  leads  to  death  at  10-15  years  after  symptom
onset.7,9,10
The  4  cases  presented  above  demonstrate  that  TTR-FAP
progression  does  not  always  follow  this  pattern.  Symptom
onset  may  occur  late  (in  patients  older  than  50),  and  the
disease  may  develop  as  purely  motor  or  sensory  polyneuro-
pathy,  with  no  autonomic  dysfunction.2—5,10
This  is  the  most  frequent  form  of  presentation  in
non-endemic  areas.  Another  form  is  mononeuropathy  pro-
gressing  to  mononeuritis  multiplex  and  eventually  a  pattern
of  polyneuropathy.2—4,8,10 Neuropathic  pain,  which  may
appear  at  onset  or  later  in  disease  progression,  is  a
burning  pain  associated  with  allodynia,  and  exhibits  a  cir-
cadian  rhythm,  worsening  in  the  evening.2,8,10 In  some
cases,  such  as  the  ﬁrst  patient’s  aunt,  the  mutation  is
non-penetrant.
TTR-FAP  is  a  genetic  but  not  necessarily  a  familial  dis-
ease.  Given  the  autosomal  dominant  inheritance  pattern,
family  history  of  the  condition  assists  in  diagnosis;  this  was
the  case  in  3  of  the  4  patients  presented.2—5,7 Family  his-
tory  of  the  disease  is  present  in  the  majority  of  cases  with
onset  at  around  the  age  of  30  years,  whereas  late-onset
cases  tend  to  be  sporadic.11 The  incomplete  penetrance  and
the  possibility  of  very  late  onset  (with  some  individuals  with
the  mutation  dying  before  presentation  of  the  disease)  can
give  rise  to  the  detection  of  apparently  sporadic  cases.2—5
There  may  also  be  cases  where  patients  are  unaware  of
their  family  history  of  the  condition  and  do  not  report
it.
TTR  variants  have  been  detected  worldwide,  especially
in  European  countries,  and  display  great  genotypic  het-
erogeneity.  The  genotype—phenotype  correlation  and  the
factors  inﬂuencing  phenotypic  variability  and  age  of  onset
are  not  fully  understood.2,5 Amino  acid  substitution  is  not
sufﬁcient  to  explain  the  condition’s  variability  in  terms
of  penetrance,  pathogenesis,  and  clinical  progression.12
In  order  to  better  understand  the  genetic  variability  of
TTR-FAP,  haplotype  characterisation  should  be  performed
for  6  single-nucleotide  polymorphisms.  In  Portugal  and
Sweden,  only  haplotype  I  has  been  associated  with  the
mutation.  Haplotype  III,  the  second  most  frequent  vari-
ant,  has  been  observed  in  individuals  from  Britain,  France,
Italy,  and  Japan.12 Soares  et  al.12 identiﬁed  10  new  poly-
morphisms:  8  caused  by  single-base  substitutions  and  2
caused  by  insertions  or  deletions  in  dinucleotide  repeat
sequences.  These  authors  hypothesise  that  age  of  onset
may  be  modulated  by  a  nearby  locus  linked  to  the  inter-
val  deﬁned  by  the  microsatellites  D18S457  and  D18S456,
associated  with  the  3-2  haplotype  on  the  accompanying
chromosome.12
A  genetic  anticipation  phenomenon  has  been  detected
in  some  Portuguese,  Swedish,  and  Japanese  families  with
early-onset  variants.  This  effect  is  more  marked  in  cases
where  the  mutation  is  transmitted  by  the  mother.5 The  lit-
erature  includes  reports  of  less  severe  phenotypes  in  cases
with  later  onset  and  longer  duration,  in  patients  with  such
compound  heterozygous  mutations  as  Agr104His/Val50Met
or  Thr119Met/Val50Met.5,13 These  additional  mutations
are  believed  to  have  a  ‘‘protective  effect’’  as  they
s
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ave  been  demonstrated  to  increase  the  stability  of  TTR
etramers.5,13
Diagnosis  may  be  complex  due  to  the  disease’s  variabil-
ty  in  terms  of  phenotype  and  age  of  onset.  Conventional
lectrophysiological  studies  detect  axonal  neuropathy.3,5,7
oderately  reduced  nerve  conduction  velocity  is  often
isinterpreted  as  a  form  of  chronic  inﬂammatory  demyeli-
ating  polyneuropathy,  perhaps  due  to  a  desire  to  provide
reatments  for  these  patients.  In  the  classic  variants,  elec-
roneurography  studies  in  early  phases  may  display  normal
esults,  as  the  disease  initially  only  affects  small  myelinated
nd  non-myelinated  ﬁbres.2,5—7
Once  polyneuropathy  is  conﬁrmed,  aetiology  may  be
ifﬁcult  to  identify  if  we  do  not  consider  late-onset  vari-
nts.  The  objective  of  tissue  biopsy  is  to  detect  amyloid
eposition.  TTR  amyloid  deposits  present  greenish-yellow
irefringence  under  polarised  light  following  Congo  red
taining2,3,5,8; this  is  a pathognomonic  feature  of  TTR-FAP.
owever,  basing  aetiological  diagnosis  on  tissue  biopsy  has
everal  limitations.  Firstly,  it  is  not  clear  which  tissue
hould  be  examined,  as  we  must  select  that  which  com-
ines  the  best  diagnostic  yield  with  the  lowest  risk  of
ndesired  consequences.4,6—8 Given  the  relative  aggressive-
ess  of  nerve  biopsy,  such  other  tissues  as  subcutaneous
at  and  salivary  gland  tissue  have  been  proposed.1,4—8 Sec-
ndly,  amyloid  deposition  is  patchy;  therefore,  absence  of
myloid  deposition  in  the  tissue  sample  tested  does  not
ule  out  the  condition.5,8 Finally,  TTR  amyloid  deposition
annot  be  conﬁrmed  by  the  detection  of  amyloid  deposits
lone.6,8 Indeed,  even  if  an  immunohistochemical  study
etermines  that  deposits  are  composed  of  TTR  amyloid,  it  is
ot  possible  to  differentiate  between  wild-type  and  mutant
TR.3,5,6,8
We  therefore  consider  full  TTR  gene  sequencing  to
e  the  diagnostic  technique  of  choice1,3,5—8;  due  to  the
ene’s  short  length  and  recent  advances  in  genetic  test-
ng,  this  is  an  inexpensive,  simple,  quick  technique  with
igh  sensitivity  and  speciﬁcity.  Given  that  TTR-FAP  can
resent  with  late  onset  and  in  the  absence  of  known  fam-
ly  history  of  the  disease,  especially  in  non-endemic  areas,
e  believe  that  TTR  sequencing  should  be  included  in
iagnostic  protocols  for  all  polyneuropathies.  If  the  dis-
ase  is  conﬁrmed,  family  members  at  risk  should  also  be
ested,  and  the  appropriate  genetic  counselling  should  be
iven.1,2,7,10
Comprehensive  testing  is  also  important,  as  this  is  a  mul-
isystem  disease.7,8
Numerous  treatments  have  been  developed  since  1990,
ith  some  still  in  the  trial  phase.14,15 The  only  treatments
urrently  accepted  are  liver  transplantation  and  tafamidis.
Liver  transplantation  is  intended  to  prevent  the  for-
ation  of  additional  amyloid  deposits  (95%  of  mutant
TR  is  synthesised  in  the  liver).2,8 The  technique  is
ntended  to  stabilise  symptoms,  but  does  not  correct
xisting  lesions.  According  to  data  from  the  Familial
myloidotic  Polyneuropathy  World  Transplant  Registry,  the
urvival  rate  following  liver  transplantation  is  85%  at
 years,  67%  at  10  years,  and  55%  at  20  years.8,16,17
he  early-onset  form  of  the  Portuguese  Val50Met  vari-
nt  responds  best  to  treatment,  with  a  10-year  survival
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188  
ate  of  74%.2,15 However,  other  mutations  are  associated
ith  poorer  outcomes,15 as  are  late-onset  forms  caused
y  the  Val50Met  mutation,  which  have  a  10-year  sur-
ival  rate  of  44%.10,13,16,18 Deposition  of  wild-type  TTR  may
ontinue  after  liver  transplantation,  and  can  cause  both
europathy2,8,18 and  cardiomyopathy.1,2 Cardiac  amyloidosis
rogression  appears  to  cease  after  liver  transplantation  in
atients  with  early-onset  TTR-FAP  caused  by  the  Val50Met
utation.1,19,20
Tafamidis  stabilises  TTR  by  inhibiting  tetramer  dissoci-
tion,  slowing  the  progression  of  the  disease.1,2,21,22 The
rug  performed  better  than  placebo  at  18  months  in  a
ouble-blind  randomised  controlled  trial  including  a  sam-
le  of  patients  with  early-stage  TTR-FAP  caused  by  the
al50Met  mutation.1,2,8,23 Based  on  these  results,  the  drug
as  approved  by  the  Spanish  Agency  for  Medicines  and
edical  Devices  for  the  treatment  of  early-stage  symp-
omatic  TTR-FAP  caused  by  the  Val50Met  mutation.1,8 It
as  also  been  studied  in  an  open-label  trial  including  21
atients  with  other  mutations;  tetramers  were  observed
o  have  stabilised  after  6  weeks  of  treatment.24 There  is
o  evidence  of  the  drug’s  efﬁcacy  at  later  stages  of  the
isease.
Besides  these  treatments,  it  is  essential  to  manage  mul-
isystem  complications.
onclusion
TR-FAP  is  a  complex,  multisystem  disease  that  is  highly
ariable  in  terms  of  presentation  and  age  of  onset.  Given
ts  high  sensitivity  and  speciﬁcity,  full  sequencing  of  the
TR  gene  should  be  included  in  diagnostic  protocols  for
ll  patients  with  progressive  polyneuropathies.  Some  treat-
ents  are  known  to  be  efﬁcacious  in  treating  the  Portuguese
ariant  of  the  disease,  but  their  usefulness  for  other  phen-
types  is  not  known;  future  research  should  address  this
atter.
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